KeyCorp reissued their buy rating on shares of Hill-Rom (NYSE:HRC) in a research report sent to investors on Thursday. They currently have a $97.00 target price on the medical technology company’s stock. KeyCorp also issued estimates for Hill-Rom’s FY2019 earnings at $5.08 EPS.
Other equities research analysts also recently issued reports about the stock. ValuEngine upgraded shares of Hill-Rom from a hold rating to a buy rating in a report on Thursday, November 16th. Stifel Nicolaus restated a buy rating and issued a $92.00 target price on shares of Hill-Rom in a report on Wednesday, November 29th. Zacks Investment Research upgraded shares of Hill-Rom from a hold rating to a buy rating and set a $90.00 price objective for the company in a research note on Friday, October 27th. Needham & Company LLC decreased their price objective on shares of Hill-Rom from $93.00 to $90.00 and set a buy rating for the company in a research note on Monday, November 6th. Finally, Barclays reiterated a buy rating and set a $100.00 price objective on shares of Hill-Rom in a research note on Wednesday, January 10th. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $95.38.
Hill-Rom (NYSE HRC) traded up $1.50 during trading on Thursday, reaching $89.30. 512,759 shares of the company were exchanged, compared to its average volume of 371,576. Hill-Rom has a 52-week low of $57.18 and a 52-week high of $89.64. The stock has a market capitalization of $5,877.82, a P/E ratio of 23.13, a price-to-earnings-growth ratio of 1.58 and a beta of 1.19. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 29th. Shareholders of record on Friday, December 15th were paid a dividend of $0.18 per share. The ex-dividend date was Thursday, December 14th. This represents a $0.72 annualized dividend and a yield of 0.81%. Hill-Rom’s dividend payout ratio is currently 36.18%.
In other Hill-Rom news, CEO John J. Greisch sold 125,241 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the completion of the sale, the chief executive officer now directly owns 280,851 shares in the company, valued at $23,195,484.09. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John J. Greisch sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the sale, the chief executive officer now owns 230,851 shares of the company’s stock, valued at $19,119,079.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 226,241 shares of company stock valued at $18,708,644. 2.20% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of HRC. Wells Fargo & Company MN lifted its position in shares of Hill-Rom by 298.4% during the second quarter. Wells Fargo & Company MN now owns 284,850 shares of the medical technology company’s stock worth $22,677,000 after purchasing an additional 213,351 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Hill-Rom by 1.3% during the second quarter. Alliancebernstein L.P. now owns 39,944 shares of the medical technology company’s stock worth $3,180,000 after purchasing an additional 520 shares in the last quarter. Seven Eight Capital LP acquired a new position in shares of Hill-Rom during the second quarter worth $127,000. Teachers Advisors LLC lifted its position in shares of Hill-Rom by 5.2% during the second quarter. Teachers Advisors LLC now owns 380,439 shares of the medical technology company’s stock worth $30,287,000 after purchasing an additional 18,922 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Hill-Rom by 1.4% during the second quarter. Ameriprise Financial Inc. now owns 195,018 shares of the medical technology company’s stock worth $15,526,000 after purchasing an additional 2,680 shares in the last quarter. 81.92% of the stock is currently owned by institutional investors and hedge funds.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.